Publication | Open Access

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

UrologyOncologyGenitourinary CancerMedicineImmune Checkpoint InhibitorFirst-line TreatmentCancer TreatmentPharmacologyVegfr-tyrosine Kinase InhibitorsMolecular Oncology